Number of subjects enrolled (N=384)

**Eliminated from LT-ATP cohort for immunogenicity**

**Group HBV_2D (N=258)**
- Returned for blood sampling (N=179)
- LT-ATP analysis for immunogenicity (N=140)

**Group HBV_3D (N=126)**
- Returned for blood sampling (N=88)
- LT-ATP analysis for immunogenicity (N=64)

**Eliminated from LT-ATP cohort for immunogenicity**

**Year 2 [M30]**
- (N=39) Returned but were eliminated previously=5
- Non-compliance with blood sampling schedule at M30=1
- Abnormal increase in antibody concentration during the LTFU at M30=1

**Year 3 [M42]**
- (N=8) Returned but were eliminated previously=6
- Received vaccine forbidden by protocol=1
- Non-compliance with blood sampling schedule=1

**Year 4 [M54]**
- (N=18) Returned but were eliminated previously=7
- Received vaccine forbidden by protocol=1
- Abnormal increase in antibody concentration=10

**Year 5 [M66]**
- (N=26) Returned but were eliminated previously=17
- Received vaccine forbidden by protocol=1
- Non-compliance with blood sampling schedule at M66=2
- Abnormal increase in antibody concentration during the LTFU at M66=6

**Challenge phase:** 144 subjects returned at the Australian and Belgian site, of which 74 subjects from the Belgian site were included in the ATP immunogenicity cohort [Exclusions: Non-evaluable participants: 67; non-compliance with blood sampling schedule: 2; Other: 1]